Hypoglycemia in type 2 diabetes mellitus patients — cerebral, cognitive, psychosocial and clinical aspects
https://doi.org/10.14341/DM12840
Abstract
The review article describes modern approaches to hypoglycemia in diabetes mellitus (DM) patients, its clinical and laboratory diagnostics, and its current classification. Hypoglycemia has the highest impact on cardiovascular morbidity and mortality, including stroke. Cerebral damage in neuroglycopenia, as well as neurological aspects in this group of patients, are discussed. The authors describe glycopenia’s influence on cerebral metabolism, counter-regulatory response, and impaired hypoglycemia recognition, as well as modern neuroimaging techniques that may enhance differential diagnostics in complex cases. The epidemiology of neurocognitive disorders in DM patients and their association with hypoglycemic conditions is outlined, together with psychosocial aspects of its consequences — both for the patient and relatives and for the medical professionals. The search for ways to reduce the burden of hypoglycemia from the standpoint of an effective and safe strategy for treating patients with type 2 diabetes does not lose its relevance, and therefore data on the prevalence of hypoglycemic conditions of varying severity when using certain classes of hypoglycemic drugs are presented. A therapeutic approach that maximizes metabolic control while reducing hypoglycemia to a minimum may determine further possibilities for personalized DM management.
About the Authors
K. V. Antonova
Research center of neurology
Russian Federation
Russian Federation
Ksenia V. Antonova, MD, PhD, leading research associate
80, Volokolamskoe highway, Moscow, 125367
Researcher ID: J-9971-2016;
Scopus Author ID: 7004672742;
eLibrary SPIN: 7737-4712
O. V. Lagoda
Research center of neurology
Russian Federation
Russian Federation
Olga V. Lagoda, MD, PhD, senior research associate
Moscow
Researcher ID: C-5395-2012;
Scopus Author ID: 6507370001;
eLibrary SPIN: 1789-4735
M. M. Tanashyan
Research center of neurology
Marine M. Tanashyan, MD, PhD, Professor
Moscow
Researcher ID: F-8483-2014;
Scopus Author ID: 6506228066;
eLibrary SPIN: 7191-1163
References
1. Gerstein HC, Miller ME, Byington RP, et al. ACCORD Study Group; Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. doi: https://doi.org/10.1056/NEJMoa0802743
2. Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011;124:993-996. doi: https://doi.org/10.1016/j.amjmed.2011.08.008
3. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. doi: https://doi.org/10.1016/S0140-6736(98)07019-6
4. Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes. 2011;4:251. doi: https://doi.org/10.1186/1756-0500-4-251
5. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. (8th edition). Diabetes mellitus. 2017;20(1S):1-112. (In Russ.). doi: https://doi.org/10.14341/DM20171S8
6. Heller SR. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155-157. doi: https://doi.org/10.2337/dc16-2215
7. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. (10th edition). Diabetes mellitus. 2021;24(1S). (In Russ.)] doi: https://doi.org/10.14341/DM12802
8. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(S1):73-84. doi: https://doi.org/10.2337/dc21-S006
9. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384-1395. doi: https://doi.org/10.2337/dc12-2480
10. Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92-101. doi: https://doi.org/10.1111/dme.12261
11. Heller SR, Choudhary P, Davies C, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147. doi: https://doi.org/10.1007/s00125-007-0599-y
12. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS One. 2015;10(6):e0126427. doi: https://doi.org/10.1371/journal.pone.0126427
13. Arrabyru PR, Qureshi IA, Skalomenos L, Rodriguez GJ. Magnetic resonance imaging changes in a 69-year old man with hypoglycemia induced brain injury: case report and literature review. Pan Afr Med J. 2019;32:131. doi: https://doi.org/10.11604/pamj.2019.32.131.17967.
14. Horsting MW, Franken MD, Meulenbelt J, et al. The etiology and outcome of non-traumatic coma in critical care: a systematic review. BMC Anesthesiol. 2015;15:65. doi: https://doi.org/10.1186/s12871-015-0041-9
15. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: https://doi.org/10.14341/DM12759
16. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159 (In Russ.). doi: https://doi.org/10.14341/DM96
17. Mayorov AY, Vikulova OK, Zheleznyakova AV, et al. Epidemiology of acute diabetes complications (coma) according to the Federal Diabetes register of the Russian Federation (2013–2016). Diabetes Mellitus. 2018;21(6):444-454. (In Russ.). doi: https://doi.org/10.14341/DM10028
18. Lawrence RD. Insulin hypoglycaemia: changes in nervous manifestations. Lancet. 1941;2:602-604. doi: https://doi.org/10.1016/S0140-6736(00)76968-6
19. McNeilly AD, McCrimmon RJ. Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. Diabetologia. 2018;61(4):743-750. doi: https://doi.org/10.1007/s00125-018-4548-8
20. Watts AG, Donovan CM. Sweet talk in the brain: glucosensing, neural networks, and hypoglycemic counterregulation. Front Neuroendocrinol. 2010;31(1):32-43. doi: https://doi.org/10.1016/j.yfrne.2009.10.006
21. Sherwin RS. Bringing Light to the Dark Side of Insulin. Diabetes. 2008;57(9):2259-2268. doi: https://doi.org/10.2337/db08-9023
22. Chakera AJ, Hurst PS, Spyer G, et al. Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes. Mol Metab. 2018;17:17-27. doi: https://doi.org/10.1016/j.molmet.2018.08.001
23. Stanley S, Moheet A, Seaquist ER. Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia. Endocr Rev. 2019;40(3):768-788. doi: https://doi.org/10.1210/er.2018-00226
24. Rehni AK, Dave KR. Impact of Hypoglycemia on Brain Metabolism During Diabetes. Mol Neurobiol. 2018;55(12):9075-9088. doi: https://doi.org/10.1007/s12035-018-1044-6
25. Martín-Timón I, Del Cañizo-Gómez FJ. Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes. 2015;6(7):912-926. doi: https://doi.org/10.4239/wjd.v6.i7.912
26. Loeb T, Ozguler A, Baer G, et al. The pathophysiology of «happy» hypoglycemia. Int J Emerg Med. 2021;14(1):23. doi: https://doi.org/10.1186/s12245-021-00348-7
27. McCrimmon RJ. Consequences of recurrent hypoglycaemia on brain function in diabetes. Diabetologia. 2021;64(5):971-977. doi: https://doi.org/10.1007/s00125-020-05369-0
28. Moghissi E, Ismail-Beigi F, Devine RC. Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr Pract. 2013;19(3):526-535. doi: https://doi.org/10.4158/EP13005.RA
29. Criner KE, Kim HN, Ali H, et al. Hypoglycemia symptoms are reduced in hospitalized patients with diabetes. J Diabetes Complications. 2021;19:107976. doi: https://doi.org/10.1016/j.jdiacomp.2021.107976
30. Alkhatatbeh MJ, Abdalqader NA, Alqudah MAY. Impaired Awareness of Hypoglycaemia in Insulin-treated Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(5):407-413. doi: https://doi.org/10.2174/1573399814666180806144937
31. Geddes J, Schopman JE, Zammitt NN, et al. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25(4):501-504. doi: https://doi.org/10.1111/j.1464-5491.2008.02413.x
32. Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulintreated Type 2 diabetes. Diabetes Res Clin Pract. 2010;87(1):64-68. doi: https://doi.org/10.1016/j.diabres.2009.10.013
33. Languren G, Montiel T, Ramírez-Lugo L, et al. Recurrent moderate hypoglycemia exacerbates oxidative damage and neuronal death leading to cognitive dysfunction after the hypoglycemic coma. J Cereb Blood Flow Metab. 2019;39(5):808-821. doi: https://doi.org/10.1177/0271678X17733640
34. Hansen TI, Olsen SE, Haferstrom ECD, et al. Cognitive deficits associated with impaired awareness of hypoglycaemia in type 1 diabetes. Diabetologia. 2017;60(6):971-979. doi: https://doi.org/10.1007/s00125-017-4233-3
35. Mattishent K, Loke YK. Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents. Front Endocrinol (Lausanne). 2021;12:571568. doi: https://doi.org/10.3389/fendo.2021.571568
36. Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. Diabetes Care. 2018;41(1):104-111.
37. Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61(1):58-65. doi: https://doi.org/10.1007/s00125-017-4422-0
38. Nunes AP, Iglay K, Radican L, et al. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obes Metab. 2017;19(10):1425-1435. doi: https://doi.org/10.1111/dom.13000
39. You Y, Liu Z, Chen Y, et al. The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Acta Diabetol. 2021;58(6):671-685. doi: https://doi.org/10.1007/s00592-020-01648-9
40. Zhang X, Jiang X, Han S, et al. Type 2 Diabetes Mellitus Is Associated with the Risk of Cognitive Impairment: a Meta-Analysis. J Mol Neurosci. 2019;68(2):251-260. doi: https://doi.org/10.1007/s12031-019-01290-3
41. Chatterjee S, Peters SA, Woodward M, et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care. 2016;39(2):300-307. doi: https://doi.org/10.2337/dc15-1588
42. Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association; 2013.
43. Whitmer RA, Gilsanz P, Quesenberry CP, et al. Association of Type 1 Diabetes and Hypoglycemic and Hyperglycemic Events and Risk of Dementia. Neurology. 2021;97(3):e275-283. doi: https://doi.org/10.1212/WNL.0000000000012243
44. Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(2):135-141. doi: https://doi.org/10.1111/dom.12587
45. Tanashyan ММ, Antonova KV, Lagoda ОV, et al. Resolved and unresolved issues of cerebrovascular disease in diabetes mellitus. Annals of clinical and experimental neurology. 2021;15(3):5-14. (In Russ.). doi: https://doi.org/10.54101/ACEN.2021.3.1
46. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke. 2019;50(12):e344-e418. doi: https://doi.org/10.1161/STR.0000000000000211
47. Saikawa R, Yamada H, Suzuki D, et al. Risk Factors of Hypoglycemic Encephalopathy and Prolonged Hypoglycemia in Patients With Severe Hypoglycemia. J Clin Med Res. 2019;11(3):213-218. doi: https://doi.org/10.14740/jocmr3728
48. Barbara G, Mégarbane B, Argaud L, et al. Functional outcome of patients with prolonged hypoglycemic encephalopathy. Ann Intensive Care. 2017;7(1):54. doi: https://doi.org/10.1186/s13613-017-0277-2
49. Adam G, Ferrier M, Patsoura S, et al. Magnetic resonance imaging of arterial stroke mimics: a pictorial review. Insights Imaging. 2018;9(5):815-831. doi: https://doi.org/10.1007/s13244-018-0637-y
50. Yong AW, Morris Z, Shuler K, et al. Acute symptomatic hypoglycaemia mimicking ischaemic stroke on imaging: a systemic review. BMC Neurol. 2012;12(1):139. doi: https://doi.org/10.1186/1471-2377-12-139
51. Katoh M, Yoshino M, Aoki T, et al. Localized reversible high signal intensities on diffusion-weighted MRI in hypoglycemia: A study of 70 cases. Asian J Neurosurg. 2016;11(4):412-415. doi: https://doi.org/10.4103/1793-5482.144196
52. Mattson MP. Excitotoxicity. In: Stress: Physiology, Biochemistry, and Pathology. Vol 12. Elsevier; 2019:125-134. doi: https://doi.org/10.1016/B978-0-12-813146-6.00011-4
53. Aslan K, Polat AV, Taskin GO, et al. Reversible Focal Splenial Lesion on Diffusion-Weighted MRI in Sulfonylurea Intoxication. J Belg Soc Radiol. 2015;99(1):34-36. doi: https://doi.org/10.5334/jbr-btr.826
54. Atay M, Aralasmak A, Sharifov R, et al. Transient cytotoxic edema caused by hypoglycemia: follow-up diffusionweighted imaging features. Emerg Radiol. 2012;19:473-475. doi: https://doi.org/10.1007/s10140-012-1043-2
55. Jeon JY, Kim SR, Kim HJ, et al. Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes: A casecontrol study. Medicine (Baltimore). 2016;95(47):e5365. doi: https://doi.org/10.1097/MD.0000000000005365
56. Smith L, Chakraborty D, Bhattacharya P, et al. Exposure to hypoglycemia and risk of stroke. Ann N Y Acad Sci. 2018;1431(1):25-34. doi: https://doi.org/10.1111/nyas.13872
57. McManus R, Ioussoufovitch S, Froats E, et al. Dynamic response of cerebral blood flow to insulin-induced hypoglycemia. Sci Rep. 2020;10:21300. doi: https://doi.org/10.1038/s41598-020-77626-6
58. Orfanos S, Toygar T, Berthold-Losleben M, et al. Investigating the impact of overnight fasting on intrinsic functional connectivity: a double-blind fMRI study. Brain Imaging and Behavior. 2018;12:1150-1159. doi: https://doi.org/10.1007/s11682-017-9777-9
59. Nicolucci A, Kovacs Burns K, Holt RIG, et al. Correlates of psychological outcomes in people with diabetes: results from the second Diabetes Attitudes, Wishes and Needs (DAWN2) study. Diabet Med. 2016;33(9):1194-1203. doi: https://doi.org/10.1111/dme.13178
60. Klimontov VV. Impaired hypoglycemia awareness in diabetes: epidemiology, mechanisms and therapeutic approaches. Diabetes Mellitus. 2018;21(6):513-523. (In Russ.). doi: https://doi.org/10.14341/DM9597
61. Kovacs Burns K, Nicolucci A, Holt RI. DAWN2 Study Group. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778-788. doi: https://doi.org/10.1111/dme.12239
62. Lawton J, Rankin D, Elliott J, et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37(1):109-115. doi: https://doi.org/10.2337/dc13-1154
63. Brown JB, Reichert SM, Valliere Y, et al. Living With Hypoglycemia: An Exploration of Patients’ Emotions: Qualitative Findings From the InHypo-DM Study, Canada. Diabetes Spectr. 2019;32(3):270-276. doi: https://doi.org/10.2337/ds18-0074
64. Felizardo V, Garcia NM, Pombo N, et al. Data-based algorithms and models using diabetics real data for blood glucose and hypoglycaemia prediction — A systematic literature review. Artif Intell Med. 2021;118:102120. doi: https://doi.org/10.1016/j.artmed.2021.102120
65. Almomani HY, Pascual CR, Al-Azzam SI, Ahmadi K. Response to impaired awareness of hypoglycaemia in a study protocol. Res Social Adm Pharm. 2021;17(10):1856-1857. doi: https://doi.org/10.1016/j.sapharm.2021.03.001
66. Druk IV, Snarskaya DI, Goroshchenya OI. Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast register data. Diabetes Mellitus. 2021;24(2):100-110.(In Russ.). doi: https://doi.org/10.14341/DM12469
67. Genere N, Montori VM. Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas. Annals of Internal Medicine. 2018;168(2):JC8. doi: https://doi.org/10.7326/ACPJC-2018-168-2-008
68. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389-394. doi: https://doi.org/10.2337/dc06-1789
69. Nicolucci A, Kovacs Burns K, Holt RIG, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: https://doi.org/10.1056/NEJMoa0802987
70. Zoungas S, Chalmers J, Neal B, et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: https://doi.org/10.1056/NEJMoa1407963
71. Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694-700. doi: https://doi.org/10.2337/dc15-2322
72. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;12;358(24):2545-2559. doi: https://doi.org/10.1056/NEJMoa0802743
73. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122(8):844-846. doi: https://doi.org/10.1161/CIRCULATIONAHA.110.960138
74. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. doi: https://doi.org/10.1056/NEJMoa0808431
75. Petunina NA, Kuzina IA, Nedosugova LV. Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug. Diabetes Mellitus. 2020;23(4):357-367. (In Russ.). doi: https://doi.org/10.14341/DM12487
76. Nusca A, Tuccinardi D, Pieralice S, et al. Platelet Effects of Antidiabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Front Pharmacol. 2021;12:670155. doi: https://doi.org/10.3389/fphar.2021.670155
77. Zaccardi F, Jacquot E, Cortese V, et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2020;22(12):2417-2426. doi: https://doi.org/10.1111/dom.14169
Supplementary files
|
|
1. Рисунок 1. Потенциальные механизмы церебральной адаптации к повторной гипогликемии. Адаптировано по Rory J. McCrimmon, 2021. Примечания: βAdR — β-адренорецептор; EphA5 — рецептор эфрина A5; TRP — каналы транзиторного рецепторного потенциала; ГАМК — гамма-аминомасляная кислота; KATФ — АТФ-зависимые калиевые каналы | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(498KB)
|
Indexing metadata ▾ | |
|
|
2. Рисунок 2. Данные МРТ. Тяжелая гипогликемия у 42-летней женщины. Визуализируется гиперинтенсивность в базальных ганглиях и валике мозолистого тела (стрелки a, c) без признаков острого ишемического повреждения в режиме ДВИ (b) и значимых изменений интракраниальных артерий (МР-ангиография) (d). Приводится по Adam G и соавт. [49]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(409KB)
|
Indexing metadata ▾ | |
Review
For citations:
Antonova K.V., Lagoda O.V., Tanashyan M.M. Hypoglycemia in type 2 diabetes mellitus patients — cerebral, cognitive, psychosocial and clinical aspects. Diabetes mellitus. 2022;25(3):288-298. (In Russ.) https://doi.org/10.14341/DM12840
Views:
6491
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
